-
-
-
-
-
-
-
Spyre Therapeutics, Inc. (SYRE) Misses Q1 EPS by 7c
-
-
-
-
-
-
-
Stifel on Spyre (SYRE): 'solid foundation for combos where we expect synergistic activity'
-
-
-
-
-
-
-
Spyre Therapeutics (SYRE) Halted, News Pending
-
-
-
-
-
-
-
Mizuho Starts Spyre (SYRE) at Outperform
-
-
-
-
-
-
-
Deutsche Bank Starts Spyre (SYRE) at Buy
-
-
-
-
-
-
-
BTIG Reiterates Buy Rating on Spyre (SYRE)
-
-
-
-
-
-
-
Spyre Therapeutics (SYRE) Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
-
420,208 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

